Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics
ACXP Price/Volume Stats
| Current price | $0.35 | 52-week high | $3.33 |
| Prev. close | $0.35 | 52-week low | $0.30 |
| Day low | $0.34 | Volume | 171,800 |
| Day high | $0.36 | Avg. volume | 280,724 |
| 50-day MA | $0.38 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 8.15M |
ACXP Stock Price Chart Interactive Chart >
Acurx Pharmaceuticals, Inc. (ACXP) Company Bio
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
ACXP Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACXP Price Returns
| 1-mo | -7.43% |
| 3-mo | -23.46% |
| 6-mo | -60.45% |
| 1-year | -85.42% |
| 3-year | -87.46% |
| 5-year | N/A |
| YTD | -57.00% |
| 2024 | -78.75% |
| 2023 | -3.77% |
| 2022 | -7.90% |
| 2021 | N/A |
| 2020 | N/A |